Sucampo Pharmaceuticals (NASDAQ:SCMP) has acquired an option to commercialize a drug candidate aimed at preventing colon cancer among a high-risk group of patients in a deal worth up to $190 million. Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
{iframe}http://www.bizjournals.com/washington/news/2016/01/11/sucampo-acquires-exclusive-option-for-cancerdrug.html?ana=e_du_pap&s=article_du&ed=2016-01-11&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1452546120{/iframe}